Roche's brain-shuttling Alzheimer's drug heads into phase 3 — and it's clearing amyloid fast

Roche has launched two identically designed phase 3 trials — TRONTIER 1 and TRONTIER 2 — to find out if trontinemab, its next-generation anti-amyloid antibody, can meaningfully slow the progression of early Alzheimer's disease. What sets trontinemab apart is its "Brainshuttle" technology: it hitches a ride on transferrin receptor 1 (TfR1), a protein that normally shuttles iron across the blood-brain barrier, allowing the drug to enter the brain far more efficiently than conventional antibodies.

Together, the trials aim to enroll ~1,600 participants across 18 countries, with dosing having begun in September 2025. Participants receive IV infusions every 4 weeks for 6 months, then shift to a less frequent maintenance schedule. The primary endpoint is change in the CDR-SB score at 18 months — the same clinical yardstick used in the lecanemab and donanemab trials.

By the Numbers:

• 91% of participants in the expanded phase 1b/2a cohort fell below the amyloid-positivity threshold after 28 weeks
• ARIA-E (brain swelling) occurred in fewer than 5% of participants — compared to 13% with lecanemab and 24% with donanemab
• ~1,600 participants enrolled across TRONTIER 1 and 2; another ~1,600 in the preclinical PrevenTRON trial
• Mean amyloid PET reduction: 89 centiloids at 12 weeks, 107 centiloids at 28 weeks

Why it matters: If trontinemab's faster, deeper amyloid clearance translates into clinical benefit with fewer safety concerns, it could become a best-in-class option in the rapidly evolving Alzheimer's treatment landscape — and potentially shift the standard of care toward earlier, safer intervention.